Save up -80% on Ibrutinib
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Imbruvica
|price without discount in nearest pharmacy. Price may vary.|
We offer free Ibrutinib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Ibrutinib every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Ibrutinib volume of distribution
Ibrutinib is rapidly absorbed after oral administration and it presents a Cmax, tmax and AUC of approximately 35 ng/ml, 1-2 hour and 953 mg.h/ml respectively. The volume of distribution at steady-state of ibrutinib is in approximately 10,000 L.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ibrutinib
Ibrutinib is a small molecule anti-cancer drug that targets B-cell malignancies. In November 2013 ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenstrom’s Macroglobulinemia (WM). Ibrutinib is marketed under the brand Imbruvica by Janssen Biotech, Inc., but was first designed and synthesized at Celera Genomics in 2007.
Ibrutinib mechanism of action
Ibrutinib is an inhibitor of Bruton s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK, leading to its inhibition. BTK plays a role in signalling through the B-cell surface receptors which results in the activation of various pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Ibrutinib has been shown to inhibit malignant B cell proliferation and survival iin vivo/i as well as substrate adhesion and cell migration.
Dosage forms of Ibrutinib
Humans and other mammals
Indication of Ibrutinib
Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenstrom’s Macroglobulinemia (WM).
Toxicity of Ibrutinib
Clinical trials have shown acceptable safety profiles of these drugs. Nonetheless, both agents have toxicity profiles that are different from those of immunochemotherapy. Moreover, the safety profile of ibrutinib is clearly distinct from that of idelalisib and this should be taken into consideration when making individual treatment decisions.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Ibrutinib on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.